

***Null Results in Brief*****Lack of Association between *CCND1* G870A Polymorphism and Risk of Esophageal Squamous Cell Carcinoma<sup>1</sup>****Chunyuan Yu, Wenfu Lu, Wen Tan, Deyin Xing, Gang Liang, Xiaoping Miao, and Dongxin Lin<sup>2</sup>**

Department of Etiology and Carcinogenesis, Cancer Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

**Introduction**

ESCC,<sup>3</sup> like most malignant tumors, is primarily a consequent of abnormal cell proliferation induced by uncontrolled cell cycle. Cyclin D1 plays an important role in the transition from G<sub>1</sub> to S phase of the cell cycle and has oncogenic properties. Overexpression of this protein is thought to be related to the development of a variety of tumors, including ESCC (1). The gene encoding cyclin D1, *CCND1*, has a common G870A polymorphism at codon 242 in exon 4 that increases the frequency of alternate splicing, leading to an altered protein (2). The altered cyclin D1 does not contain the sequences involved in protein turnover and, thus, may have a longer acting half-life. It has been suggested that this polymorphism in the *CCND1* gene confers susceptibility to certain cancers (3–5).

In this study, we analyzed DNA samples from a hospital-based case-control study in a Chinese population to test the hypothesis that the *CCND1* G870A polymorphism may be a genetic risk modifier for ESCC.

**Materials and Methods**

This study included 321 patients with ESCC and 345 age- and gender-matched healthy controls. Patients were consecutively recruited from January 1998 to December 2000 at the Cancer Hospital, Chinese Academy of Medical Sciences (Beijing, China). Population controls were accrued from a database of nutritional survey conducted in the same regions. Most of the cases and controls have been characterized in a molecular epidemiological study described elsewhere (6). The *CCND1* G870A genotypes were determined by PCR-restriction fragment length polymorphism method as described previously (4). The ORs and their 95% CIs calculated by unconditional logistic regression models and adjusted for age, sex, and smoking status were used to estimate risk of ESCC for the *CCND1* polymorphism.

**Results and Discussion**

The allele frequencies for *CCND1* 870G and 870A were 0.424 and 0.576, respectively, among controls and 0.457 and 0.543,

**Table 1** *CCND1* G870A genotypes in cases and controls and their association with the risk of esophageal cancer

Genotype	Cases (n = 321)		Controls (n = 345)		OR (95% CI) <sup>a</sup>
	n	(%)	n	(%)	
GG	68	(21.2)	58	(16.8)	1.00
GA	157	(48.9)	177	(51.3)	0.80 (0.53–1.21)
AA	96	(29.9)	110	(31.9)	0.80 (0.51–1.25)

<sup>a</sup> ORs and 95% CIs were calculated by logistic regression model with the GG genotype as the reference group and adjusted for age, gender, and smoking status.

respectively, among cases with ESCC. The distribution of three *CCND1* G870A genotypes among cases were not significantly different from that among controls and, thus, the polymorphism did not associated with risk of ESCC (Table 1). In addition, no evidence for interaction between the polymorphism and tobacco smoking was observed.

Although this study had sufficient power (80%) to detect risk >1.8, we observed no association between the *CCND1* G870A polymorphism and risk of ESCC. These results indicate that the *CCND1* G870A genotypes themselves may not be involved in the predisposition to develop ESCC. However, in this study, we did not assay other genetic variations of cell cycle related proteins such as retinoblastoma and p21, which interact with cyclin D1 and also play key roles in cell cycle regulation. Without such information, we cannot exclude the possibility that the *CCND1* G870A polymorphism may confer susceptibility to ESCC via functional interaction with other genetic polymorphisms. Therefore, the results of this study highlight the need for additional studies on polygene analysis.

**References**

- Jiang, W., Zhang, Y., Scott, M. K., Monica, C. H., Regina, M. S., Lu, S., Curtis, C. H., Ruggero, M., and Bernard, W. Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. *Proc. Natl. Acad. Sci. USA*, 90: 9026–9030, 1993.
- Betticher, D. C., Thatcher, N., Altermatt, H. J., Hoban, P., Ryder, D. J., and Heighway, J. Alternate splicing produces a novel cyclin D1 transcript. *Oncogene*, 11: 1005–1011, 1995.
- McKay, J. A., Douglas, J. J., Ross, V. G., Curran, S., Murray, G. I., Cassidy, J., and McLeod, H. J. Cyclin D1 protein expression and gene polymorphism in colorectal cancer. *Int. J. Cancer*, 88: 77–81, 2000.
- Zheng, Y., Shen, H., Erich, M. S., Wang, L., Susan, A. E., Sara, S. S., Marsha, L. F., Margaret, R. S., and Wei, Q. Cyclin D1 polymorphism and risk for squamous cell carcinoma of the head and neck: a case-control study. *Carcinogenesis (Lond.)*, 22: 1195–1199, 2001.
- Wang, L., Habuchi, T., Takahashi, T., Mitsumori, K., Kamoto, T., Kakehi, Y., Kakinuma, H., Sato, K., Nakamura, A., Ogawa, O., and Kato, T. Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer. *Carcinogenesis (Lond.)*, 23: 257–264, 2002.
- Song, C., Xing, D., Tan, W., Wei, Q., and Lin, D. Methylene tetrahydrofolate reductase polymorphisms increase risk of esophageal squamous cell carcinoma in a Chinese population. *Cancer Res.*, 61: 3272–3275, 2001.

Received 10/11/02; revised 10/11/02; accepted 11/22/02.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

<sup>1</sup> Supported by National Natural Science Foundation Grant 39825122 and from State Key Basic Research Program Grant G1998051204.

<sup>2</sup> To whom requests for reprints should be addressed, at Department of Etiology and Carcinogenesis, Cancer Institute, Chinese Academy of Medical Sciences, Beijing 100021, China. Fax: 86-10-67722460; E-mail: dlin@public.bta.net.cn.

<sup>3</sup> The abbreviations used are: ESCC, esophageal squamous cell carcinoma; OR, odds ratio; CI, confidence interval.

# BLOOD CANCER DISCOVERY

## Lack of Association between *CCND1* G870A Polymorphism and Risk of Esophageal Squamous Cell Carcinoma

Chunyu Yu, Wenfu Lu, Wen Tan, et al.

*Cancer Epidemiol Biomarkers Prev* 2003;12:176.

**Updated version** Access the most recent version of this article at:  
<http://cebp.aacrjournals.org/content/12/2/176>

**Cited articles** This article cites 6 articles, 2 of which you can access for free at:  
<http://cebp.aacrjournals.org/content/12/2/176.full#ref-list-1>

**Citing articles** This article has been cited by 2 HighWire-hosted articles. Access the articles at:  
<http://cebp.aacrjournals.org/content/12/2/176.full#related-urls>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link  
<http://cebp.aacrjournals.org/content/12/2/176>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.